An overview of benvitimod for the treatment of psoriasis: a narrative review

References

• Wu JJ, Lynde CW, Kleyn CE, et al. Identification of key research needs for topical therapy treatment of psoriasis – a consensus paper by the international psoriasis council. J Eur Acad Dermatol Venereol. 2016;30:1115–1119.
   PubMed Web of Science ®Google Scholar
• Reid C, Griffiths CEM. Psoriasis and treatment: past, present and future aspects Acta Dermato-Venereologica. 2020:100 doi:https://doi.org/10.2340/00015555-3386.
   Google Scholar
• Ference JD, Last AR. Choosing topical corticosteroids. Vol. 79. United States: American Family Physician; 2009.
   Google Scholar
• Bissonnette R, Stein Gold L, Rubenstein DS, et al. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent. J Am Acad Dermatol. 2021;84:1059–1067.
   PubMed Web of Science ®Google Scholar
• Neavin DR, Liu D, Ray B, et al. The role of the aryl hydrocarbon receptor (AHR) in immune and inflammatory diseases. Int J Mol Sci. 2018;19:3851.
   Web of Science ®Google Scholar
• Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110–2119.
   PubMed Web of Science ®Google Scholar
• Haarmann-Stemmann T, Sutter TR, Krutmann J, et al. The mode of action of tapinarof may not only depend on the activation of cutaneous aryl hydrocarbon receptor signaling but also on its antimicrobial activity. J Am Acad Dermatol. 2021;85:e33–e34.
   PubMed Web of Science ®Google Scholar
• Furue M, Tsuji G, Mitoma C, et al. Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor. J Dermatol Sci. 2015Nov;80(2):83–88. Epub 2015 Jul 26. PMID: 26276439.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Stein Gold L, Strober B, et al. Tapinarof Cream 1% QD for the treatment of plaque psoriasis: efficacy and safety in two pivotal phase 3 trials. SKIN J Cutaneous Med. 2020;4(6):75.
   Google Scholar
• Stein Gold L, Bhatia N, Tallman AM, et al. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: secondary efficacy and patient-reported outcomes. J Am Acad Dermatol. 2021;84(3):624–631.
   PubMed Web of Science ®Google Scholar
• Cai L, Chen GH, Lu QJ, et al., A double-blind, randomized, placebo- And positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J (Engl). 133(24): 2905–2909. 2020.
   PubMed Web of Science ®Google Scholar
• Jett J, McLaughlin M, Lee M, et al. Maximal use study of tapinarof cream 1% in subjects with extensive plaque psoriasis. SKIN J Cutaneous Med. 2020;4(6):s74.
   Google Scholar
• Bissonnette R, Bolduc C, Maari C, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol. 2012;26(12):1516–1521.
   PubMed Web of Science ®Google Scholar
• Robbins K, Bissonnette R, Maeda-Chubachi T, et al. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol. 2019;80(3):714–721.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Gold LS, Rubenstein DS, et al. Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapy. J Am Acad Dermatol. 2021;85:e39–e40.
   PubMed Web of Science ®Google Scholar
• Konstantinou MP, Jendoubi F, Hegazy S, et al. Tapinarof-induced folliculitis: the paradigm of activation of the aryl hydrocarbon signaling pathway. J Am Acad Dermatol. 2021;85:e37–e38.
   PubMed Web of Science ®Google Scholar
• Denison MS, Soshilov AA, He G, et al. Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol Sci. 2011;124(1):1–22.
   PubMed Web of Science ®Google Scholar
• Cline A, Feldman SR. Aryl hydrocarbon receptor activation: from coal to dioxin. J Dermatological Treat. 2018;29:215–216.
   PubMed Web of Science ®Google Scholar
• Furue M, Takahara M, Nakahara T, et al. Role of AhR/ARNT system in skin homeostasis. Arch Dermatol Res. 2014;306(9):769–779.
   PubMed Web of Science ®Google Scholar
• Lamas B, Natividad JM, Sokol H. Aryl hydrocarbon receptor and intestinal immunity. Mucosal Immunol. 2018Jul;11(4):1024–1038. Epub 2018 Apr 7. PMID: 29626198.
   PubMed Web of Science ®Google Scholar
• Assaf J, Sarkis J, Tomb R. Tapinarof and the future of topical treatments in plaque psoriasis. J Am Acad Dermatol. 2021;84:e283–e284.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Chaudhari K, Syed BA. The psoriasis drugs market. Nat Rev Drug Discov. 2015;14(11):745–746.
   PubMed Web of Science ®Google Scholar
• Reinheimer C, Büttner D, Proschak E, et al. Anti-tubercular activity of a natural stilbene and its synthetic derivatives. GMS infectious diseases. 2018: 6
   Google Scholar
• Zhao L, Chen X, Cai L, et al. Randomized, double-blind, placebo-controlled, multiple-dose study of the safety, tolerability and pharmacokinetics of benvitimod, a candidate drug for the treatment of psoriasis. J Clin Pharm Ther. 2014;39(4):418–423.
   PubMed Web of Science ®Google Scholar
• Zang YN, Jiang DL, Cai L, et al. Use of a dose-response model to guide future clinical trials of benvitimod cream to treat mild and moderate psoriasis. Int J Clin Pharmacol Ther. 2016;54(2):87–95.
   PubMed Web of Science ®Google Scholar
• Silverberg NB. Pediatric psoriasis: an update. Ther Clin Risk Manag. 2009;5:849–856.
   PubMedGoogle Scholar
• Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin. 2006;24:167–197.
   PubMed Web of Science ®Google Scholar
• Park HB, Goddard TN, Oh J, et al. Bacterial autoimmune drug metabolism transforms an immunomodulator into structurally and functionally divergent antibiotics. Angewandte Chemie - International Edition. 2020;59(20):7871–7880.
   PubMed Web of Science ®Google Scholar
• van Den Bogaard Eh, Esser C, Perdew GH, et al. The aryl hydrocarbon receptor at the forefront of host-microbe interactions in the skin: a perspective on current knowledge gaps and directions for future research and therapeutic applications. Exp Dermatol. 2021;30(10):1477–1483.
   PubMed Web of Science ®Google Scholar
• Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci. 2019;20:5424.
   PubMed Web of Science ®Google Scholar
• Mayba JN, Gooderham MJ. Review of atopic dermatitis and topical therapies. J Cutan Med Surg. 2017;21:227–236.
   PubMed Web of Science ®Google Scholar
• Patel NU, D’Ambra V, Feldman SR. Increasing adherence with topical agents for atopic dermatitis. Am J Clin Dermatol. 2017;18(3):323–332.
   PubMed Web of Science ®Google Scholar
• Hogue L, Cardwell LA, Roach C, et al., Psoriasis and atopic dermatitis “resistant” to topical treatment responds rapidly to topical desoximetasone spray. J Cutan Med Surg. 23(2): 157–163. 2019.
   PubMed Web of Science ®Google Scholar
• Murage MJ, Tongbram V, Feldman SR, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Vol. 12, United Kingdom: Patient Preference and Adherence; 2018.
   Google Scholar
• Bass A, Anderson K, Feldman S. Interventions to increase treatment adherence in pediatric atopic dermatitis: a systematic review. J Clin Med. 2015;4(2):231–242.
   PubMed Web of Science ®Google Scholar
• Davis SA, Liu HC, Yu CH, et al. Underuse of early follow-up visits: a missed opportunity to improve patients’ adherence. Journal of Drugs in Dermatology. 2014;13(7).
   Web of Science ®Google Scholar
• Thorneloe RJ, Griffiths CEM, Emsley R, et al. Intentional and unintentional medication non-adherence in psoriasis: the role of patients’ medication beliefs and habit strength. J Invest Dermatol. 2018;138(4):785–794.
   PubMed Web of Science ®Google Scholar
• Svendsen MT, Feldman S, Tiedemann SN, et al. Improving psoriasis patients’ adherence to topical drugs: a systematic review. J Dermatological Treat. 2020;31:776–785.
   PubMed Web of Science ®Google Scholar
• Bashyam AM, Cuellar-Barboza A, Ghamrawi RI, et al. Placebo tailoring improves patient satisfaction of treatment plans in atopic dermatitis. J Am Acad Dermatol. 2020;83(3):944–946.
   PubMed Web of Science ®Google Scholar
• Curry ZA, Johnson MC, Unrue EL, et al. Caregiver willingness to treat atopic dermatitis is not much improved by anchoring. J Dermatological Treat. 2019;30(5):471–474.
   PubMed Web of Science ®Google Scholar